These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
586 related articles for article (PubMed ID: 26467384)
1. Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma. Klanova M; Andera L; Brazina J; Svadlenka J; Benesova S; Soukup J; Prukova D; Vejmelkova D; Jaksa R; Helman K; Vockova P; Lateckova L; Molinsky J; Maswabi BC; Alam M; Kodet R; Pytlik R; Trneny M; Klener P Clin Cancer Res; 2016 Mar; 22(5):1138-49. PubMed ID: 26467384 [TBL] [Abstract][Full Text] [Related]
2. Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1. Li L; Pongtornpipat P; Tiutan T; Kendrick SL; Park S; Persky DO; Rimsza LM; Puvvada SD; Schatz JH Leukemia; 2015 Aug; 29(8):1702-12. PubMed ID: 25882699 [TBL] [Abstract][Full Text] [Related]
3. Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma. Dupont T; Yang SN; Patel J; Hatzi K; Malik A; Tam W; Martin P; Leonard J; Melnick A; Cerchietti L Oncotarget; 2016 Jan; 7(3):3520-32. PubMed ID: 26657288 [TBL] [Abstract][Full Text] [Related]
4. Diffuse Large B Cell Lymphoma Cell Line U-2946: Model for MCL1 Inhibitor Testing. Quentmeier H; Drexler HG; Hauer V; MacLeod RA; Pommerenke C; Uphoff CC; Zaborski M; Berglund M; Enblad G; Amini RM PLoS One; 2016; 11(12):e0167599. PubMed ID: 27907212 [TBL] [Abstract][Full Text] [Related]
5. Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma. Chiron D; Dousset C; Brosseau C; Touzeau C; Maïga S; Moreau P; Pellat-Deceunynck C; Le Gouill S; Amiot M Oncotarget; 2015 Apr; 6(11):8750-9. PubMed ID: 25797245 [TBL] [Abstract][Full Text] [Related]
6. Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma. de Jong MRW; Langendonk M; Reitsma B; Nijland M; van den Berg A; Ammatuna E; Visser L; van Meerten T Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31801186 [TBL] [Abstract][Full Text] [Related]
7. CDK7 inhibitor THZ1 inhibits MCL1 synthesis and drives cholangiocarcinoma apoptosis in combination with BCL2/BCL-XL inhibitor ABT-263. Huang T; Ding X; Xu G; Chen G; Cao Y; Peng C; Shen S; Lv Y; Wang L; Zou X Cell Death Dis; 2019 Aug; 10(8):602. PubMed ID: 31399555 [TBL] [Abstract][Full Text] [Related]
8. Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma. Kuo HP; Ezell SA; Schweighofer KJ; Cheung LWK; Hsieh S; Apatira M; Sirisawad M; Eckert K; Hsu SJ; Chen CT; Beaupre DM; Versele M; Chang BY Mol Cancer Ther; 2017 Jul; 16(7):1246-1256. PubMed ID: 28428442 [TBL] [Abstract][Full Text] [Related]
9. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Chen S; Dai Y; Harada H; Dent P; Grant S Cancer Res; 2007 Jan; 67(2):782-91. PubMed ID: 17234790 [TBL] [Abstract][Full Text] [Related]
11. The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib. Hikita H; Takehara T; Shimizu S; Kodama T; Shigekawa M; Iwase K; Hosui A; Miyagi T; Tatsumi T; Ishida H; Li W; Kanto T; Hiramatsu N; Hayashi N Hepatology; 2010 Oct; 52(4):1310-21. PubMed ID: 20799354 [TBL] [Abstract][Full Text] [Related]
12. NOXA genetic amplification or pharmacologic induction primes lymphoma cells to BCL2 inhibitor-induced cell death. Liu Y; Mondello P; Erazo T; Tannan NB; Asgari Z; de Stanchina E; Nanjangud G; Seshan VE; Wang S; Wendel HG; Younes A Proc Natl Acad Sci U S A; 2018 Nov; 115(47):12034-12039. PubMed ID: 30404918 [TBL] [Abstract][Full Text] [Related]
13. Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia. Cervantes-Gomez F; Lamothe B; Woyach JA; Wierda WG; Keating MJ; Balakrishnan K; Gandhi V Clin Cancer Res; 2015 Aug; 21(16):3705-15. PubMed ID: 25829398 [TBL] [Abstract][Full Text] [Related]
14. The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma. Esteve-Arenys A; Valero JG; Chamorro-Jorganes A; Gonzalez D; Rodriguez V; Dlouhy I; Salaverria I; Campo E; Colomer D; Martinez A; Rymkiewicz G; Pérez-Galán P; Lopez-Guillermo A; Roué G Oncogene; 2018 Apr; 37(14):1830-1844. PubMed ID: 29353886 [TBL] [Abstract][Full Text] [Related]
15. Anti-apoptotic MCL1 Protein Represents Critical Survival Molecule for Most Burkitt Lymphomas and BCL2-negative Diffuse Large B-cell Lymphomas. Klanova M; Kazantsev D; Pokorna E; Zikmund T; Karolova J; Behounek M; Renesova N; Sovilj D; Kelemen CD; Helman K; Jaksa R; Havranek O; Andera L; Trneny M; Klener P Mol Cancer Ther; 2022 Jan; 21(1):89-99. PubMed ID: 34728569 [TBL] [Abstract][Full Text] [Related]
16. Targeted inhibition of PI3Kα/δ is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL. Bojarczuk K; Wienand K; Ryan JA; Chen L; Villalobos-Ortiz M; Mandato E; Stachura J; Letai A; Lawton LN; Chapuy B; Shipp MA Blood; 2019 Jan; 133(1):70-80. PubMed ID: 30322870 [TBL] [Abstract][Full Text] [Related]
17. Targeting BCL2 with venetoclax is a promising therapeutic strategy for "double-proteinexpression" lymphoma with Uchida A; Isobe Y; Asano J; Uemura Y; Hoshikawa M; Takagi M; Miura I Haematologica; 2019 Jul; 104(7):1417-1421. PubMed ID: 30523053 [TBL] [Abstract][Full Text] [Related]
18. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin. Witham J; Valenti MR; De-Haven-Brandon AK; Vidot S; Eccles SA; Kaye SB; Richardson A Clin Cancer Res; 2007 Dec; 13(23):7191-8. PubMed ID: 18056200 [TBL] [Abstract][Full Text] [Related]
19. γ-Secretase inhibition promotes cell death, Noxa upregulation, and sensitization to BH3 mimetic ABT-737 in human breast cancer cells. Séveno C; Loussouarn D; Bréchet S; Campone M; Juin P; Barillé-Nion S Breast Cancer Res; 2012 Jun; 14(3):R96. PubMed ID: 22703841 [TBL] [Abstract][Full Text] [Related]
20. MCL1 and BCL-xL levels in solid tumors are predictive of dinaciclib-induced apoptosis. Booher RN; Hatch H; Dolinski BM; Nguyen T; Harmonay L; Al-Assaad AS; Ayers M; Nebozhyn M; Loboda A; Hirsch HA; Zhang T; Shi B; Merkel CE; Angagaw MH; Wang Y; Long BJ; Lennon XQ; Miselis N; Pucci V; Monahan JW; Lee J; Kondic AG; Im EK; Mauro D; Blanchard R; Gilliland G; Fawell SE; Zawel L; Schuller AG; Strack P PLoS One; 2014; 9(10):e108371. PubMed ID: 25289887 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]